Watching BIOTRON closely. 2 Scenarios:
1. Break of internal trend within the symmetrical triangle will see us return to the .065-.080 region (AREA OF INTEREST).
-We've had 2 bounces on the .382 Fib region creating a double top @ .115 Equilibrium
-Break of internal uptrend trendline.
-Currently broken the center band of bollinger bands.
-We've also had a death cross on MACD and is starting to spread.
-Waiting on break of support at .088
2. If POSITIVE results are announced shortly for any of BIOTRONS Projects/Programs (Anti Viral Drug Program, HIV Program, HBV Program) We should see a break out of Symmetrical Triangle.
-Break of downtrend possible.
-Retest of .011 Equilibrium VERY possible.
-New Market Structure will form with Higher LOW & Higher HIGH.
-Volume will be brought back into the market.
-My next target would be major resistance at .014
A very interesting company with real world prospects. I have been following them since the earlier in the year, with Phase 2 HIV-1 Clinical Trials being successful, HBV Pre-Clinical Trials and work on Anti Viral Drug Development with a keen interest on Covid-19.
These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
1. Break of internal trend within the symmetrical triangle will see us return to the .065-.080 region (AREA OF INTEREST).
-We've had 2 bounces on the .382 Fib region creating a double top @ .115 Equilibrium
-Break of internal uptrend trendline.
-Currently broken the center band of bollinger bands.
-We've also had a death cross on MACD and is starting to spread.
-Waiting on break of support at .088
2. If POSITIVE results are announced shortly for any of BIOTRONS Projects/Programs (Anti Viral Drug Program, HIV Program, HBV Program) We should see a break out of Symmetrical Triangle.
-Break of downtrend possible.
-Retest of .011 Equilibrium VERY possible.
-New Market Structure will form with Higher LOW & Higher HIGH.
-Volume will be brought back into the market.
-My next target would be major resistance at .014
A very interesting company with real world prospects. I have been following them since the earlier in the year, with Phase 2 HIV-1 Clinical Trials being successful, HBV Pre-Clinical Trials and work on Anti Viral Drug Development with a keen interest on Covid-19.
These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!